Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by Bully88on May 13, 2021 10:55am
167 Views
Post# 33191379

RE:Stage website

RE:Stage websiteGood Morning,

These tests have been on Stage Zero's website for years now.

I was using them as a reference when we were speculating what we thought Stage zero would charge for Aristotle.

I definitely think that the Revenue growth in their Cancer Tests were severely underappreciated.

As per the Sedar Posted MD&A

                                  Year ended December 31
                                     2020                2019 $ $
Cancer Testing          473,063               138,704
COVID Testing          3678747                  - 

Roughly a 340% growth in Cancer Testing Revenues.

This was Pre Aristotle and Care Oncology revenues.

Those are pretty good growth numbers for a company in this position.

I have always been a very positive sided investor of stage zero as i believe their product they have are revolutionary and will change the game in Cancer Testing, which is a huge market.

I do however stand true to comments I made that this was a Lose 50% risk or Gain 1000's % reward stock.

We all expected a major partnership announcement with instant access to major revenues.

What we got was a solid business plan to grow Aristotle slow and steady and grow.

Sprinkle on top the Mis managed timing of releasing our financials, thus creating more bad faith in management, this is why we lost 50% of our share price.

Remember. ALOT of us had bought at sub .60c prices and even selling above $1.00 would have gained us some pretty awesome returns.

I was one of them.
 
The way I see this companies future now, is a slow and steady growth opportunity.

Covid revenues are great. 

They are allowing us to complete our mission without incurring more debt or further diluting our shares.  They are basically paying for our purchase of our Cancer clinics which are going to be our base model of real Cancer revenue. 

They will not last forever.

Stagezero has discussed this, that they projected covid revenue to grow and accelerate for 18-24 months and then slowly tamper off where Aristotle testing revenues would take over.

They are fulfilling their projections to a Tee

Does this stock have room to fall more? yes of course. 

But I truly believe we are on the lower end of the spectrum of what this SP should be at this point now. as we have formed a stron resistance in the .60's again.

From here on out this company will have to show growth in their Cancer testing revenues.

This is the base philosphy of business.

build a product and continue to grow your revenues through various streams.

I am not as heavily weighted in my investment in this company as i like i just said I took alot off the table at a very good R.O.I

I am however still heavily invested personally in this company, as I have lost family to Cancer and I know how big of an impact this company can have.

Remember, theres no money in Curing Cancer. The money is in Treating Cancer.

And SZLS is now perfectly alligned to benefit from all the aspects of Cancer treatment. From doctor consultations, to testing to treatment.  SZLS now has all of the pieces to grow into a major Cancer company.

Will i make millions off this company? most probably not.

Will I grow proud of myself for investing in a company that can change lives the way SZLS can. 

Absolutely.

Cheers 

Bully





<< Previous
Bullboard Posts
Next >>